Assertio Therapeutics Inc (ASRT)vsTeva Pharma Industries Ltd ADR (TEVA)
ASRT
Assertio Therapeutics Inc
$16.51
+17.93%
HEALTHCARE · Cap: $86.17M
TEVA
Teva Pharma Industries Ltd ADR
$29.46
+1.10%
HEALTHCARE · Cap: $33.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 14438% more annual revenue ($17.26B vs $118.71M). TEVA leads profitability with a 8.2% profit margin vs -25.6%. TEVA appears more attractively valued with a PEG of 1.43. TEVA earns a higher WallStSmart Score of 73/100 (B).
ASRT
Hold38
out of 100
Grade: F
TEVA
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ASRT.
Margin of Safety
+39.4%
Fair Value
$56.63
Current Price
$29.46
$27.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.3%
Earnings expanding 40.0% YoY
Generating 1.0B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -28.2% — below average capital efficiency
Revenue declined 57.9%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ASRT
The strongest argument for ASRT centers on Price/Book.
Bull Case : TEVA
The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bear Case : ASRT
The primary concerns for ASRT are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : TEVA
The primary concerns for TEVA are Altman Z-Score.
Key Dynamics to Monitor
ASRT profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.
ASRT carries more volatility with a beta of 0.79 — expect wider price swings.
TEVA is growing revenue faster at 11.4% — sustainability is the question.
TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (73/100 vs 38/100) and 11.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Assertio Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Assertio Holdings, Inc., a commercial pharmaceutical company, provides medications in the areas of neurology, hospital, and pain and inflammation. The company is headquartered in Lake Forest, Illinois.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?